Business Context and Reporting Period
This Form 6-K is filed by BiondVax Pharmaceuticals Ltd. for the month of June 2018. The registrant is a foreign private issuer based in Ness Ziona, Israel, focused on developing M-001, a product candidate designed as a primer for influenza vaccines.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for the period. The primary financial event disclosed is the receipt of a €6 million tranche disbursement from the European Investment Bank (EIB). This disbursement is part of a larger Finance Contract for up to €20 million intended to fund up to 50% of the development and marketing costs for M-001.
Material Changes
The material change reported is the execution of the first tranche of the EIB financing agreement announced in June 2017. This represents a significant liquidity event for the company, providing immediate capital for its product development pipeline.
Guidance, Outlook, and Risks
Management commentary is limited to the confirmation of the EIB funding receipt. The filing does not contain specific forward-looking guidance, updated risk factors, or discussion of contingencies beyond the context of the financing agreement. The outlook remains tied to the development and marketing of the M-001 candidate.
Investor Verification Checklist
- Verify the terms and conditions of the full €20 million EIB Finance Contract.
- Confirm the specific milestones required to trigger subsequent tranches of the EIB funding.
- Review the attached press release (Exhibit 99.1) for detailed use of proceeds.
- Check subsequent filings for updates on the development status of the M-001 product candidate.